Use access key #2 to skip to page content.

IBDvalueinvestin (98.35)

DCTH at day lows but $7.50 target raised to $21



April 22, 2010 – Comments (0)

Delcath target raised to $21 at Wedbush following PHP system phase III data (10.85 ) : Wedbush notes last night co reported positive data from Delcath Systems' Percutaneous Hepatic Perfusion (PHP) System Phase III study in patients with melanoma that has metastasized to the liver. Importantly, in addition to the highly positive top-line hPFS data, firm's checks suggest that at ASCO, it can expect to see multiple secondary endpoints that point to a positive clinical benefit to patients, including overall survival trends. Tgt to $21 from $7.50.

0 Comments – Post Your Own

Featured Broker Partners